{"id":"NCT01188811","sponsor":"VA Office of Research and Development","briefTitle":"Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)","officialTitle":"Lipoic Acid for Neuroprotection in Secondary Progressive MS","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-10","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2010-08-26","resultsPosted":"2017-02-02","lastUpdate":"2017-02-02"},"enrollment":54,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis, Chronic Progressive"],"interventions":[{"type":"DRUG","name":"lipoic acid","otherNames":["alpha lipoic acid"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm 1: lipoic acid","type":"EXPERIMENTAL"},{"label":"Arm 2: placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.","primaryOutcome":{"measure":"Brain Atrophy by MRI","timeFrame":"% change brain volume from baseline to year 2","effectByArm":[{"arm":"Lipoic Acid","deltaMin":-0.4,"sd":0.7},{"arm":"Placebo","deltaMin":-1.3,"sd":1.1}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["30477834","28680916"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":28},"commonTop":["Fall","Urinary Tract Infection","Flu-like symptoms","Nausea","Diarrhea"]}}